Prime Medicine, Inc.
PRME
$3.66
-$0.01-0.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -31.59% | 9.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -31.59% | 9.87% | |||
| Cost of Revenue | -21.10% | 1,267.00% | |||
| Gross Profit | 20.80% | -1,933.52% | |||
| SG&A Expenses | 31.49% | -14.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.42% | 1.30% | |||
| Operating Income | 9.94% | -1.12% | |||
| Income Before Tax | 8.90% | 3.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.90% | 3.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.90% | 3.82% | |||
| EBIT | 9.94% | -1.12% | |||
| EBITDA | 10.29% | -1.12% | |||
| EPS Basic | 17.52% | 22.60% | |||
| Normalized Basic EPS | 18.58% | 19.25% | |||
| EPS Diluted | 17.52% | 22.60% | |||
| Normalized Diluted EPS | 18.58% | 19.25% | |||
| Average Basic Shares Outstanding | 10.47% | 24.24% | |||
| Average Diluted Shares Outstanding | 10.47% | 24.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||